<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Neurosci.</journal-id>
<journal-title>Frontiers in Molecular Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-5099</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnmol.2023.1298560</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Differential expression of <italic>PSMC4</italic>, <italic>SKP1</italic>, and <italic>HSPA8</italic> in Parkinson&#x2019;s disease: insights from a Mexican mestizo population</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Salas-Leal</surname> <given-names>Alma C.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/817184/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Salas-Pacheco</surname> <given-names>Sergio M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1533140/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Hern&#x00E1;ndez-Cosa&#x00ED;n</surname> <given-names>Erik I.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>V&#x00E9;lez-V&#x00E9;lez</surname> <given-names>Lilia M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Antuna-Salcido</surname> <given-names>Elizabeth I.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Castellanos-Ju&#x00E1;rez</surname> <given-names>Francisco X.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/800518/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>M&#x00E9;ndez-Hern&#x00E1;ndez</surname> <given-names>Edna M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/414706/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Llave-Le&#x00F3;n</surname> <given-names>Osmel La</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Qui&#x00F1;ones-Canales</surname> <given-names>Gerardo</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Arias-Carri&#x00F3;n</surname> <given-names>Oscar</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/68884/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Sandoval-Carrillo</surname> <given-names>Ada A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/445588/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Salas-Pacheco</surname> <given-names>Jos&#x00E9; M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/143396/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Instituto de Investigaci&#x00F3;n Cient&#x00ED;fica, Universidad Ju&#x00E1;rez del Estado de Durango</institution>, <addr-line>Durango</addr-line>, <country>M&#x00E9;xico</country></aff>
<aff id="aff2"><sup>2</sup><institution>Hospital General Santiago Ram&#x00F3;n y Cajal-ISSSTE</institution>, <addr-line>Durango</addr-line>, <country>M&#x00E9;xico</country></aff>
<aff id="aff3"><sup>3</sup><institution>Unidad de Trastornos del Movimiento y Sue&#x00F1;o, Hospital General Dr. Manuel Gea Gonz&#x00E1;lez</institution>, <addr-line>Ciudad de M&#x00E9;xico</addr-line>, <country>M&#x00E9;xico</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Hai Sun, The State University of New Jersey, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Sung Ung Kang, Johns Hopkins University, United States; Sangjune Kim, Chungbuk National University, Republic of Korea</p></fn>
<corresp id="c001">&#x002A;Correspondence: Jos&#x00E9; M. Salas-Pacheco, <email>jsalas_pacheco@hotmail.com</email></corresp>
<corresp id="c002">Ada A. Sandoval-Carrillo, <email>adda-sandoval@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>16</volume>
<elocation-id>1298560</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>09</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>11</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Salas-Leal, Salas-Pacheco, Hern&#x00E1;ndez-Cosa&#x00ED;n, V&#x00E9;lez-V&#x00E9;lez, Antuna-Salcido, Castellanos-Ju&#x00E1;rez, M&#x00E9;ndez-Hern&#x00E1;ndez, Llave-Le&#x00F3;n, Qui&#x00F1;ones-Canales, Arias-Carri&#x00F3;n, Sandoval-Carrillo and Salas-Pacheco.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Salas-Leal, Salas-Pacheco, Hern&#x00E1;ndez-Cosa&#x00ED;n, V&#x00E9;lez-V&#x00E9;lez, Antuna-Salcido, Castellanos-Ju&#x00E1;rez, M&#x00E9;ndez-Hern&#x00E1;ndez, Llave-Le&#x00F3;n, Qui&#x00F1;ones-Canales, Arias-Carri&#x00F3;n, Sandoval-Carrillo and Salas-Pacheco</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Parkinson&#x2019;s disease (PD) is a complex neurodegenerative condition characterized by alpha-synuclein aggregation and dysfunctional protein degradation pathways. This study investigates the differential gene expression of pivotal components (<italic>UBE2K</italic>, <italic>PSMC4</italic>, <italic>SKP1</italic>, and <italic>HSPA8</italic>) within these pathways in a Mexican-Mestizo PD population compared to healthy controls. We enrolled 87 PD patients and 87 controls, assessing their gene expression levels via RT-qPCR. Our results reveal a significant downregulation of <italic>PSMC4</italic>, <italic>SKP1</italic>, and <italic>HSPA8</italic> in the PD group (<italic>p</italic> = 0.033, <italic>p</italic> = 0.003, and <italic>p</italic> = 0.002, respectively). Logistic regression analyses establish a strong association between PD and reduced expression of <italic>PSMC4</italic>, <italic>SKP1</italic>, and <italic>HSPA8</italic> (OR = 0.640, 95% CI = 0.415&#x2013;0.987; OR = 0.000, 95% CI = 0.000&#x2013;0.075; OR = 0.550, 95% CI = 0.368&#x2013;0.823, respectively). Conversely, <italic>UBE2K</italic> exhibited no significant association or expression difference between the groups. Furthermore, we develop a gene expression model based on <italic>HSPA8</italic>, <italic>PSMC4</italic>, and <italic>SKP1</italic>, demonstrating robust discrimination between healthy controls and PD patients. Notably, the model&#x2019;s diagnostic efficacy is particularly pronounced in early-stage PD. In conclusion, our study provides compelling evidence linking decreased gene expression of <italic>PSMC4</italic>, <italic>SKP1</italic>, and <italic>HSPA8</italic> to PD in the Mexican-Mestizo population. Additionally, our gene expression model exhibits promise as a diagnostic tool, particularly for early-stage PD diagnosis.</p>
</abstract>
<kwd-group>
<kwd>Parkinson&#x2019;s disease</kwd>
<kwd><italic>UBE2K</italic></kwd>
<kwd><italic>PSMC4</italic></kwd>
<kwd><italic>SKP1</italic></kwd>
<kwd><italic>HSPA8</italic></kwd>
<kwd>protein degradation systems</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="33"/>
<page-count count="7"/>
<word-count count="4396"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Brain Disease Mechanisms</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>1 Introduction</title>
<p>Parkinson&#x2019;s disease (PD) stands as a multifaceted neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons. Nevertheless, the intricate mechanisms underlying this condition remain shrouded in uncertainty. Emerging evidence has spotlighted dysregulation in the clearance and degradation of alpha-synuclein as a pivotal player in the pathogenesis of neuronal demise in PD (<xref ref-type="bibr" rid="B17">Mehra et al., 2019</xref>; <xref ref-type="bibr" rid="B10">Jankovic and Tan, 2020</xref>). At the crux of this degradation nexus lies the concerted interplay among chaperones, the ubiquitin-proteasome system (UPS), and autophagy-lysosomal pathways.</p>
<p>The UPS pathway orchestrates the disposal of damaged proteins through a meticulous tagging process involving three key enzymes: activating enzyme E1, conjugating enzyme E2, and ligase enzyme E3 (<xref ref-type="bibr" rid="B2">Chen and Dou, 2010</xref>). Subsequent to this tagging, the protein-ubiquitin conjugates are recognized and degraded by the 26S proteasome, a large proteolytic assembly resident within the cytosol and nucleus of eukaryotic cells. This proteasome is composed of a 20S core particle and a 19S regulatory particle (<xref ref-type="bibr" rid="B11">Jarome and Devulapalli, 2018</xref>).</p>
<p>Intriguingly, prior inquiries into the expression of genes associated with these degradation machineries in blood and brain tissues of individuals afflicted by PD, including <italic>PSMC4</italic> (an integral component of the 19S proteasomal particle), <italic>SKP1</italic> (an essential constituent of the SCF complex endowed with E3 ubiquitin ligase activity), <italic>UBE2K</italic> (an ubiquitin-conjugating enzyme E2K), and <italic>HSPA8</italic> (a 70kDa heat shock protein exerting chaperone functions), have yielded divergent results (<xref ref-type="bibr" rid="B7">Grunblatt et al., 2004</xref>; <xref ref-type="bibr" rid="B15">Mandel et al., 2005</xref>, <xref ref-type="bibr" rid="B13">2012b</xref>; <xref ref-type="bibr" rid="B18">Molochnikov et al., 2012</xref>; <xref ref-type="bibr" rid="B28">Su et al., 2018</xref>). This divergence may stem from genetic disparities among diverse populations, imparting an element of complexity to our understanding of PD etiology.</p>
<p>Thus, the principal objective of our study is to scrutinize the expression profiles of these genes in peripheral blood samples sourced from the Mexican-mestizo population. By doing so, we aim to ascertain whether these gene expression patterns possess the potential to serve as a risk profile for PD.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>2 Materials and methods</title>
<sec id="S2.SS1">
<title>2.1 Study participants and ethical criteria</title>
<p>We collected samples from a cohort of 87 PD patients and 87 healthy, age-matched controls devoid of familial or personal histories of neurodegenerative diseases. PD diagnoses were confirmed by neurologists employing the United Kingdom Parkinson&#x2019;s disease Society Brain Bank (UKPDSBB) diagnostic criteria. Participants were recruited from three prominent public hospitals located in central and northwest Mexico: Hospital General Dr. Manuel Gea Gonzalez in Mexico City, Hospital General 450, and Hospital General Santiago Ram&#x00F3;n y Cajal in Durango City. This study secured the ethical approval of each participating hospital&#x2019;s ethics committee.</p>
<p>All procedures adhered strictly to the ethical principles outlined in the 1964 Helsinki Declaration and its subsequent amendments. Informed written consent was obtained from all participants, with the additional requirement of a family member&#x2019;s consent for each participant. Pertinent patient data, encompassing age, gender, presence of depression, cognitive status, age of disease onset, and Unified Parkinson&#x2019;s disease Rating Scale (UPDRS) scores, were meticulously documented.</p>
</sec>
<sec id="S2.SS2">
<title>2.2 Blood collection, RNA extraction, cDNA synthesis, and RT-qPCR</title>
<p>Venous whole blood was collected from the subjects in Tempus Blood RNA tubes and reserved at &#x2212;80 C until RNA extraction. We processed samples according to the manufacturer protocol to extract total RNA using MagMAX for Stabilized Blood Tubes RNA Isolation kit (Life Technologies, Norway). We then synthesized cDNA using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer&#x2019;s instructions. Concentration and purity of RNA and cDNA were determined using NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific Inc., Germering, Germany) and cDNA was stored at &#x2212;20 C until further evaluation. Gene expression levels of <italic>UBE2K, HSPA8, SKP1</italic>, and <italic>PSMC4</italic> were measured through relative quantification (RQ) of 125 ng/mL of cDNA by Real-time quantitative PCR (RT-qPCR) using a QuantStudio 3 System (Applied Biosystems, Carlsbad, CA, USA) with TaqMan assays (<italic>UBE2K</italic> assay ID Hs00193507_m1, <italic>HSPA8</italic> assay ID Hs03044880_gH, <italic>SKP1</italic> assay ID Hs00429069_m1 and <italic>PSMC4</italic> assay ID Hs00197826_m1, Applied Biosystems). The expression was normalized to the <italic>RPLP0</italic> gene (<italic>RPLP0</italic> assay ID Hs00420895_gH, Applied Biosystems). The reaction conditions were: initial hold of 10 min at 95 C; 40 cycles of denaturation for 15 s at 95 C and annealing for 1 min at 60 C.</p>
</sec>
<sec id="S2.SS3">
<title>2.3 Statistical methods</title>
<p>Statistical analyses were executed using SPSS Statistics 20.0 software. Quantitative data are presented as mean &#x00B1; standard deviation (SD). For normally distributed parameters, differences were assessed using a two-tailed t-test, while non-parametric tests were applied to analyze mRNA and protein levels. Logistic regression was employed to investigate the association between mRNA expression and PD, with significant P-values retaining relevance in constructing predictive classifier models. Receiver operating characteristic curve (ROC) data were derived from predictive probabilities generated via multivariate logistic regression, encompassing all PD patients and a subset of early-stage PD patients (those with less than 5 and 3 years of disease evolution). Correlations were evaluated via Spearman correlation with the two-tailed test of significance. <italic>P</italic>-value &#x003C; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="S3" sec-type="results">
<title>3 Results</title>
<sec id="S3.SS1">
<title>3.1 Demographic and clinical characteristics</title>
<p><xref ref-type="table" rid="T1">Table 1</xref> presents a comprehensive overview of the demographic and clinical attributes of both the PD cases and control subjects. Comparative analysis of these variables between the two groups unveiled significant differences on the presence of depression (<italic>p</italic> = 0.040).</p>
<table-wrap position="float" id="T1">
<label>TABLE 1</label>
<caption><p>Demographic and clinical characteristics of study participants.</p></caption>
<table cellspacing="5" cellpadding="5" frame="box" rules="all">
<thead>
<tr>
<td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;"></td>
<td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;">PD<break/> <italic>n</italic> = 87</td>
<td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;">Control<break/> <italic>n</italic> = 87</td>
<td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;"><italic>p</italic></td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Age &#x00B1; SD</td>
<td valign="top" align="center">70.4 &#x00B1; 9.27</td>
<td valign="top" align="center">70.03 &#x00B1; 9.19</td>
<td valign="top" align="center">0.793<sup>+</sup></td>
</tr>
<tr>
<td valign="top" align="left" colspan="4" style="background-color: #dcdcdc;"><bold>Gender</bold></td>
</tr>
<tr>
<td valign="top" align="left">Female</td>
<td valign="top" align="center">42 (48.3%)</td>
<td valign="top" align="center">42 (48.3%)</td>
<td valign="top" align="center" rowspan="2">1<sup>++</sup></td>
</tr>
<tr>
<td valign="top" align="left">Male</td>
<td valign="top" align="center">45 (51.7%)</td>
<td valign="top" align="center">45 (51.7%)</td>
</tr>
<tr>
<td valign="top" align="left">Minimum Age</td>
<td valign="top" align="center">53</td>
<td valign="top" align="center">53</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Maximum Age</td>
<td valign="top" align="center">94</td>
<td valign="top" align="center">92</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">Depression (HAM-D)</td>
<td valign="top" align="center">67 (77.2%)</td>
<td valign="top" align="center">53 (61.3%)</td>
<td valign="top" align="center">0.040<sup>++</sup></td>
</tr>
<tr>
<td valign="top" align="left">Cognitive impairment (MMSE)</td>
<td valign="top" align="center">44 (51.2%)</td>
<td valign="top" align="center">45 (52.3%)</td>
<td valign="top" align="center">0.890<sup>++</sup></td>
</tr>
<tr>
<td valign="top" align="left">Age of onset &#x00B1; SD</td>
<td valign="top" align="center">64.9 &#x00B1; 9.6</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">PD Early stage (smaller or equal<break/> to 5 years of diagnosis)</td>
<td valign="top" align="center">52 (59.8%)</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">PD Early stage (smaller or equal<break/> to 3 years of diagnosis)</td>
<td valign="top" align="center">31 (17.8%)</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">UPDRS total score &#x00B1; SD</td>
<td valign="top" align="center">68.6 &#x00B1; 31.3</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">UPDRS PART I &#x00B1; SD</td>
<td valign="top" align="center">10.5 &#x00B1; 6.9</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">UPDRS PART II &#x00B1; SD</td>
<td valign="top" align="center">14.9 &#x00B1; 9.4</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">UPDRS PART III &#x00B1; SD</td>
<td valign="top" align="center">39.9 &#x00B1; 19.7</td>
<td/>
<td/>
</tr>
<tr>
<td valign="top" align="left">UPDRS PART IV &#x00B1; SD</td>
<td valign="top" align="center">2.3 &#x00B1; 4.8</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p><sup>+</sup>Student t-test, <sup>++</sup>chi-square test.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S3.SS2">
<title>3.2 Gene expression profiles</title>
<p><xref ref-type="fig" rid="F1">Figure 1</xref> provides a graphical representation of the observed gene expression levels in both the PD and control groups. Utilizing Relative Quantification (RQ) analysis, we identified a significant reduction in the expression levels of <italic>HSPA8</italic>, <italic>SKP1</italic>, and <italic>PSMC4</italic> among PD cases (<italic>p</italic> = 0.002, <italic>p</italic> = 0.003, and <italic>p</italic> = 0.033, respectively). To further elucidate their relevance to PD, logistic regression analysis was conducted, adjusting for sex and age (<xref ref-type="table" rid="T2">Table 2</xref>). The results unequivocally substantiated the associations of <italic>HSPA8</italic>, <italic>SKP1</italic>, and <italic>PSMC4</italic> with PD. However, <italic>UBE2K</italic> exhibited no statistically significant association with the disease.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>Relative quantification (RQ) of mRNA. Comparison between control and PD groups of mRNA levels of <bold>(A)</bold> <italic>UBE2K</italic>, <bold>(B)</bold> <italic>HSPA8</italic>, <bold>(C)</bold> <italic>SKP1</italic>, and <bold>(D)</bold> <italic>PSMC4</italic>. Outliers are denoted by dots. &#x002A;&#x002A;<italic>p</italic> &#x003C; 0.005, &#x002A;<italic>p</italic> &#x003C; 0.05.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fnmol-16-1298560-g001.tif"/>
</fig>
<table-wrap position="float" id="T2">
<label>TABLE 2</label>
<caption><p>Association of gene expression levels with PD adjusted by sex and age.</p></caption>
<table cellspacing="5" cellpadding="5" frame="box" rules="all">
<thead>
<tr>
<td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;"></td>
<td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;">OR<xref ref-type="table-fn" rid="t2fns1">&#x002A;</xref></td>
<td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;">95% CI</td>
<td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;"><italic>p</italic></td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left"><italic>UBE2K</italic></td>
<td valign="top" align="center">0.943</td>
<td valign="top" align="center">0.711&#x2013;1.250</td>
<td valign="top" align="center">0.681</td>
</tr>
<tr>
<td valign="top" align="left"><italic>HSPA8</italic></td>
<td valign="top" align="center">0.550</td>
<td valign="top" align="center">0.368&#x2013;0.823</td>
<td valign="top" align="center">0.004</td>
</tr>
<tr>
<td valign="top" align="left"><italic>SKP1</italic></td>
<td valign="top" align="center">0.000</td>
<td valign="top" align="center">0.000&#x2013;0.075</td>
<td valign="top" align="center">0.012</td>
</tr>
<tr>
<td valign="top" align="left"><italic>PSMC4</italic></td>
<td valign="top" align="center">0.640</td>
<td valign="top" align="center">0.415&#x2013;0.987</td>
<td valign="top" align="center">0.044</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t2fns1"><p>OR, Odds Ratio; CI, confidence interval. &#x002A;Adjusted by sex and age.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S3.SS3">
<title>3.3 Influence of depression on gene expression</title>
<p>We observed a notable disparity in the frequency of depression between the PD and control groups (<xref ref-type="table" rid="T1">Table 1</xref>), consequently, we conducted a gene expression association analysis considering while adjusting for sex, age, and depression. The findings revealed that, even after factoring in depression, the previously established associations for <italic>HSPA8</italic> and <italic>SKP1</italic> remained statistically significant (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap position="float" id="T3">
<label>TABLE 3</label>
<caption><p>Association of gene expression levels with PD adjusted by sex, age and depression.</p></caption>
<table cellspacing="5" cellpadding="5" frame="box" rules="all">
<thead>
<tr>
<td valign="top" align="left" style="color:#ffffff;background-color: #7f8080;"></td>
<td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;">OR<xref ref-type="table-fn" rid="t3fns1">&#x002A;</xref></td>
<td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;">95% CI</td>
<td valign="top" align="center" style="color:#ffffff;background-color: #7f8080;"><italic>p</italic></td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left"><italic>UBE2K</italic></td>
<td valign="top" align="center">1.041</td>
<td valign="top" align="center">0.758&#x2013;1.430</td>
<td valign="top" align="center">0.803</td>
</tr>
<tr>
<td valign="top" align="left"><italic>HSPA8</italic></td>
<td valign="top" align="center">0.461</td>
<td valign="top" align="center">0.278&#x2013;0.764</td>
<td valign="top" align="center">0.003</td>
</tr>
<tr>
<td valign="top" align="left"><italic>SKP1</italic></td>
<td valign="top" align="center">0.000</td>
<td valign="top" align="center">0.000&#x2013;0.000</td>
<td valign="top" align="center">0.001</td>
</tr>
<tr>
<td valign="top" align="left"><italic>PSMC4</italic></td>
<td valign="top" align="center">0.798</td>
<td valign="top" align="center">0.499&#x2013;1.278</td>
<td valign="top" align="center">0.348</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t3fns1"><p>OR, Odds Ratio; CI, confidence interval. &#x002A;Adjusted by sex, age and depression.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S3.SS4">
<title>3.4 Correlation analysis of gene expression</title>
<p>An exploratory analysis of gene expression within the control group unveiled intriguing interrelationships among the four genes under scrutiny. Specifically, we observed a positive correlation between the expression levels of <italic>HSPA8</italic>, <italic>UBE2K</italic>, and <italic>PSMC4</italic>. Conversely, <italic>SKP1</italic> exhibited a negative correlation with these three genes (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Similar results were observed when testing the PD group, except for the correlation between <italic>SKP1</italic> and <italic>PSMC4</italic>, which was not statistically significant (<italic>p</italic> = 0.165, <xref ref-type="fig" rid="F2">Figure 2B</xref>). Furthermore, a correlation analysis within the PD group revealed no significant correlation between PD severity (measured with UPDRS) and the expression levels of <italic>SKP1A</italic> (<italic>p</italic> = 0.455), <italic>PSMC4</italic> (<italic>p</italic> = 0.655), <italic>UBE2K</italic> (<italic>p</italic> = 0.305) and <italic>HSPA8</italic> (<italic>p</italic> = 0.786).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>Correlation analysis of gene expression in both control <bold>(A)</bold> and PD <bold>(B)</bold> groups. R = Spearman correlations coefficient.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fnmol-16-1298560-g002.tif"/>
</fig>
</sec>
<sec id="S3.SS5">
<title>3.5 Predictive utility of gene expression</title>
<p>To assess the potential utility of gene expression as a prognostic biomarker for PD, we constructed Receiver Operating Characteristic (ROC) curves based on predictive values derived from logistic regression. We formulated three distinct models, each contingent on the duration of PD evolution (<xref ref-type="fig" rid="F3">Figure 3</xref>). Evaluation of these curves unveiled increasing values for the Area under the Curve (AUC), signifying that a shorter duration of PD evolution positively impacts the predictive value of the model. At a cut-off point of 0.25 it was possible to distinguish between PD individuals and healthy controls with sensitivity and specificity values of 77% and 72.3%, respectively (<xref ref-type="fig" rid="F3">Figure 3C</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>Receiver Operating Characteristic (ROC) Curves for Discriminating Between PD Patients and Controls. The curve represents the relationship between specificity and sensitivity based on the predictive probability derived from gene expression levels of <italic>HSPA8</italic>, <italic>SKP1</italic>, and <italic>PSMC4</italic>. <bold>(A)</bold> Comparison of PD patients versus healthy controls. <bold>(B)</bold> Comparison of PD patients with a disease duration of less than 5 years versus healthy controls. <bold>(C)</bold> Comparison of PD patients with a disease duration of less than 3 years versus healthy controls.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fnmol-16-1298560-g003.tif"/>
</fig>
</sec>
</sec>
<sec id="S4" sec-type="discussion">
<title>4 Discussion</title>
<p>In this study, we delved into the gene expression profiles of <italic>UBE2K</italic>, <italic>HSPA8</italic>, <italic>SKP1</italic>, and <italic>PSMC4</italic> within both control and PD cohorts to evaluate their potential implications in the pathogenesis of PD. Our findings unveiled marked reductions in the gene expression levels of <italic>HSPA8</italic>, <italic>SKP1</italic>, and <italic>PSMC4</italic> in the PD group in comparison to the control group.</p>
<p>The <italic>PSMC4</italic> gene encodes the proteasomal protein S6 ATPase, a constituent of the 19S regulatory subunit essential for the assembly of the 26S proteasome (<xref ref-type="bibr" rid="B4">Dahlmann, 2016</xref>). Previous investigations have identified the presence of the <italic>PSMC4</italic> protein in Lewy bodies, demarcating their periphery within dopaminergic neurons of the substantia nigra (<xref ref-type="bibr" rid="B8">Gr&#x00FC;nblatt et al., 2018</xref>). Notably, our observations concerning <italic>PSMC4</italic> gene expression in blood align with prior reports (<xref ref-type="bibr" rid="B18">Molochnikov et al., 2012</xref>). Similar reductions in mRNA levels of <italic>PSMC4</italic> within the substantia nigra pars compacta (SNpc) of the brain have been documented in PD patients when compared to controls (<xref ref-type="bibr" rid="B7">Grunblatt et al., 2004</xref>; <xref ref-type="bibr" rid="B6">Gr&#x00FC;nblatt, 2012</xref>). The correlation between gene expression levels, protein presence in the SNpc, and localization within Lewy bodies in post-mortem SN samples from PD patients suggests the potential biological relevance of our findings derived from blood samples (<xref ref-type="bibr" rid="B16">Marx et al., 2007</xref>; <xref ref-type="bibr" rid="B8">Gr&#x00FC;nblatt et al., 2018</xref>). Recent research indicated a decreased expression of <italic>PSMC4</italic> mRNA, particularly evident after 3 years of disease progression, and established a correlation with disease severity. Nevertheless, this correlation, while noteworthy, did not achieve the requisite strength to be incorporated into a predictive PD classifier model (<xref ref-type="bibr" rid="B22">Rabey et al., 2020</xref>).</p>
<p>The <italic>SKP1</italic> gene encodes the SKP1 protein, involved in the formation of the SCF complex, endowed with E3 ubiquitin ligase activity. This intricate assembly plays a pivotal role in identifying target proteins for degradation via the ubiquitin-proteasome system, primarily through interactions with F-box proteins (<xref ref-type="bibr" rid="B33">Zheng et al., 2002</xref>). SKP1 exhibits the ability to directly interact with FBXO7, an F-box protein implicated in the regulation of alpha-synuclein (<xref ref-type="bibr" rid="B32">Zhao et al., 2013</xref>; <xref ref-type="bibr" rid="B3">Conedera et al., 2016</xref>). Perturbations in SKP1 function could potentially contribute to PD development by disrupting the proper degradation of proteins, leading to an accrual of misfolded proteins (<xref ref-type="bibr" rid="B14">Mandel et al., 2012a</xref>). Consistent with our findings, reduced expression levels of <italic>SKP1</italic> in both the SNpc and blood have been documented in PD (<xref ref-type="bibr" rid="B7">Grunblatt et al., 2004</xref>; <xref ref-type="bibr" rid="B12">Mandel et al., 2009</xref>; <xref ref-type="bibr" rid="B18">Molochnikov et al., 2012</xref>). It is important to underscore that silencing of <italic>SKP1</italic> has been experimentally demonstrated to promote the accumulation of cytoplasmic inclusions reminiscent of Lewy bodies while concurrently exerting a negative regulatory effect on <italic>HSPA8</italic> gene expression (<xref ref-type="bibr" rid="B5">Fishman-Jacob et al., 2009</xref>; <xref ref-type="bibr" rid="B14">Mandel et al., 2012a</xref>). <italic>In vitro</italic> studies have further validated that SKP1 deficiency exacerbates PD pathology, culminating in the formation of Lewy body-like inclusions and ensuing neuronal demise (<xref ref-type="bibr" rid="B13">Mandel et al., 2012b</xref>). Notably, our identification of a negative correlation between <italic>SKP1</italic> expression and all three genes within our control group implies that SKP1 may potentially exert its effects only in the presence of cellular damage. Consequently, normal <italic>SKP1</italic> expression might not suffice to deter PD progression in the absence of underlying cellular damage.</p>
<p>HSC70 protein, encoded by the <italic>HSPA8</italic> gene, stands as an integral component of Lewy bodies in PD (<xref ref-type="bibr" rid="B8">Gr&#x00FC;nblatt et al., 2018</xref>). This chaperone protein, orchestrates the selective degradation of proteins, maintaining cellular proteostasis through chaperone-mediated autophagy, a process contingent on lysosomes (<xref ref-type="bibr" rid="B19">Nie et al., 2021</xref>). Our findings regarding <italic>HSPA8</italic> expression harmonize with prior assessments encompassing transcript and protein levels in both peripheral blood and brain tissues (<xref ref-type="bibr" rid="B7">Grunblatt et al., 2004</xref>; <xref ref-type="bibr" rid="B29">Tanaka, 2009</xref>; <xref ref-type="bibr" rid="B1">Alvarez-Erviti et al., 2010</xref>; <xref ref-type="bibr" rid="B20">Papagiannakis et al., 2015</xref>). Nonetheless, it is worth noting that <xref ref-type="bibr" rid="B18">Molochnikov et al. (2012)</xref> reported an elevation in <italic>HSPA8</italic> expression levels in PD patients, although the biological significance of this elevation was not explained.</p>
<p>The differential expression profiles observed in our study suggest potential perturbations in protein degradation pathways within our study population, which could underlie the abnormal aggregation of proteins integral to Lewy bodies and consequently impact dopaminergic neuron function.</p>
<p>Our comprehensive ROC curve analysis illuminates the potential utility of <italic>HSPA8</italic>, <italic>PSMC4</italic>, and <italic>SKP1</italic> gene expression levels as effective discriminators between healthy controls and individuals with PD. Similar results in a multi- center study in the German, Italian and Israeli population suggest the ability of a five-gene panel, including <italic>HSPA8</italic>, <italic>PSMC4</italic>, <italic>SKP1</italic> and <italic>UBE2K</italic>, to diagnose early/mild PD in Italy, Germany, and Israel populations (<xref ref-type="bibr" rid="B18">Molochnikov et al., 2012</xref>).</p>
<p>As depicted in <xref ref-type="fig" rid="F3">Figure 3</xref>, this discriminatory capacity is further augmented when PD has a shorter duration. These observations collectively indicate that the expression levels of these genes experience significant reductions during the early stages of PD. Importantly, these reductions may be partially ameliorated through medication-induced epigenetic modifications.</p>
<p>Previously, it has been shown that the accuracy of clinical diagnosis for PD could range from 53&#x2013;74% (<xref ref-type="bibr" rid="B31">Tolosa et al., 2006</xref>). More recently, accuracies ranging from 69% to over 90% have been reported in some populations with advanced symptoms (<xref ref-type="bibr" rid="B23">Rizzo et al., 2016</xref>). However, a recent study describes an accuracy of 26% in clinical diagnoses for PD in patients with recent symptom onset (<xref ref-type="bibr" rid="B21">Prajjwal et al., 2023</xref>). Our model suggests an accuracy of 79.1% for predicting PD in the early stage, as indicated by the AUC values obtained, suggesting it as a promising tool for PD prediction.</p>
<p>One noteworthy limitation of our study resides in the fact that all PD patients were undergoing L-dopa treatment, a factor that has been previously suggested to potentially influence gene expression patterns (<xref ref-type="bibr" rid="B30">Taravini et al., 2016</xref>). Reports indicated that L-dopa influenced DNA methylation, resulting in reduced expression of the <italic>SNCA</italic> gene. Nevertheless, it was suggested that its epigenetic influence on other genes could have been possible (<xref ref-type="bibr" rid="B25">Schmitt et al., 2015</xref>; <xref ref-type="bibr" rid="B9">Guhathakurta et al., 2017</xref>; <xref ref-type="bibr" rid="B27">Song et al., 2017</xref>).</p>
<p>The variances in our findings when compared to other populations underscore the necessity of exploring associations between single nucleotide polymorphisms (SNPs) and gene expression to elucidate these disparities (<xref ref-type="bibr" rid="B26">Soldner et al., 2016</xref>; <xref ref-type="bibr" rid="B24">Salas-Leal et al., 2021</xref>). Consequently, future endeavors should encompass genotyping to modulate transcript variants, shedding light on these discrepancies. Additionally, the execution of cohort studies will be indispensable in delineating the potential utility of our model as a predictive tool for PD.</p>
</sec>
<sec id="S5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="S6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Comit&#x00E9; de &#x00E9;tica del Hospital General Dr. Manuel Gea Gonz&#x00E1;lez, Comit&#x00E9; de &#x00E9;tica del Hospital General 450 and Comit&#x00E9; de &#x00E9;tica del Hospital General Santiago Ram&#x00F3;n y Cajal. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x2019; legal guardians/next of kin.</p>
</sec>
<sec id="S7" sec-type="author-contributions">
<title>Author contributions</title>
<p>AS-L: Conceptualization, Methodology, Writing&#x2212;original draft. SS-P: Data curation, Formal analysis, Methodology, Writing&#x2212;review and editing. EH-C: Data curation, Formal analysis, Writing&#x2212;review and editing. LV-V: Investigation, Methodology, Writing&#x2212;review and editing. EA-S: Investigation, Methodology, Writing&#x2212;review and editing. FC-J: Investigation, Methodology, Writing&#x2212;review and editing. EM-H: Data curation, Methodology, Writing&#x2212;review and editing. OL-L: Data curation, Formal analysis, Writing&#x2212;review and editing. GQ-C: Data curation, Investigation, Writing&#x2212;review and editing. OA-C: Data curation, Formal analysis, Writing&#x2212;review and editing. AS-C: Conceptualization, Formal analysis, Funding acquisition, Supervision, Writing&#x2212;review and editing. JS-P: Conceptualization, Methodology, Supervision, Visualization, Writing&#x2212;review and editing.</p>
</sec>
</body>
<back>
<sec id="S8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of the article. This study was supported by the grants from CONACyT (FOSISS 2014:233092 and CB 2015:253857 giving to AS-C).</p>
</sec>
<ack><p>We would like to thank all the participants in the project and their families for their willingness and cooperation throughout the development of this study.</p>
</ack>
<sec id="S9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="S10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Erviti</surname> <given-names>L.</given-names></name> <name><surname>Rodriguez-Oroz</surname> <given-names>M.</given-names></name> <name><surname>Cooper</surname> <given-names>J.</given-names></name> <name><surname>Caballero</surname> <given-names>C.</given-names></name> <name><surname>Ferrer</surname> <given-names>I.</given-names></name> <name><surname>Obeso</surname> <given-names>J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Chaperone-mediated autophagy markers in Parkinson disease brains.</article-title> <source><italic>Arch. Neurol.</italic></source> <volume>67</volume> <fpage>1464</fpage>&#x2013;<lpage>1472</lpage>. <pub-id pub-id-type="doi">10.1001/archneurol.2010.198</pub-id> <pub-id pub-id-type="pmid">20697033</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>D.</given-names></name> <name><surname>Dou</surname> <given-names>Q.</given-names></name></person-group> (<year>2010</year>). <article-title>The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.</article-title> <source><italic>Curr. Protein Pept. Sci.</italic></source> <volume>11</volume> <fpage>459</fpage>&#x2013;<lpage>470</lpage>. <pub-id pub-id-type="doi">10.2174/138920310791824057</pub-id> <pub-id pub-id-type="pmid">20491623</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conedera</surname> <given-names>S.</given-names></name> <name><surname>Apaydin</surname> <given-names>H.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Yoshino</surname> <given-names>H.</given-names></name> <name><surname>Ikeda</surname> <given-names>A.</given-names></name> <name><surname>Matsushima</surname> <given-names>T.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>FBXO7 mutations in Parkinson&#x2019;s disease and multiple system atrophy.</article-title> <source><italic>Neurobiol. Aging</italic></source> <volume>40</volume>:<fpage>192.e1</fpage>&#x2013;<lpage>192.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.01.003</pub-id> <pub-id pub-id-type="pmid">26882974</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahlmann</surname> <given-names>B.</given-names></name></person-group> (<year>2016</year>). <article-title>Mammalian proteasome subtypes: Their diversity in structure and function.</article-title> <source><italic>Arch. Biochem. Biophys.</italic></source> <volume>591</volume> <fpage>132</fpage>&#x2013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.abb.2015.12.012</pub-id> <pub-id pub-id-type="pmid">26724758</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fishman-Jacob</surname> <given-names>T.</given-names></name> <name><surname>Reznichenko</surname> <given-names>L.</given-names></name> <name><surname>Youdim</surname> <given-names>M.</given-names></name> <name><surname>Mandel</surname> <given-names>S. A.</given-names></name></person-group> (<year>2009</year>). <article-title>A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A.</article-title> <source><italic>J. Biol. Chem.</italic></source> <volume>284</volume> <fpage>32835</fpage>&#x2013;<lpage>32845</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.034223</pub-id> <pub-id pub-id-type="pmid">19748892</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gr&#x00FC;nblatt</surname> <given-names>E.</given-names></name></person-group> (<year>2012</year>). <article-title>Parkinson&#x2019;s disease: Molecular risk factors.</article-title> <source><italic>Parkinsonism Relat. Disord.</italic></source> <volume>18</volume> <fpage>S45</fpage>&#x2013;<lpage>S48</lpage>. <pub-id pub-id-type="doi">10.1016/S1353-8020(11)70016-5</pub-id> <pub-id pub-id-type="pmid">22166452</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grunblatt</surname> <given-names>E.</given-names></name> <name><surname>Mandel</surname> <given-names>S.</given-names></name> <name><surname>Jacob-Hirsch</surname> <given-names>J.</given-names></name> <name><surname>Zeligson</surname> <given-names>S.</given-names></name> <name><surname>Amariglo</surname> <given-names>N.</given-names></name> <name><surname>Rechavi</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes.</article-title> <source><italic>J. Neural Transm.</italic></source> <volume>111</volume> <fpage>1543</fpage>&#x2013;<lpage>1573</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-004-0212-1</pub-id> <pub-id pub-id-type="pmid">15455214</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gr&#x00FC;nblatt</surname> <given-names>E.</given-names></name> <name><surname>Ruder</surname> <given-names>J.</given-names></name> <name><surname>Monoranu</surname> <given-names>C.</given-names></name> <name><surname>Riederer</surname> <given-names>P.</given-names></name> <name><surname>Youdim</surname> <given-names>M.</given-names></name> <name><surname>Mandel</surname> <given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Differential alterations in metabolism and proteolysis-related proteins in human Parkinson&#x2019;s Disease substantia nigra.</article-title> <source><italic>Neurotox Res.</italic></source> <volume>33</volume> <fpage>560</fpage>&#x2013;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1007/s12640-017-9843-5</pub-id> <pub-id pub-id-type="pmid">29218503</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guhathakurta</surname> <given-names>S.</given-names></name> <name><surname>Bok</surname> <given-names>E.</given-names></name> <name><surname>Evangelista</surname> <given-names>B.</given-names></name> <name><surname>Kim</surname> <given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Deregulation of &#x03B1;-synuclein in Parkinson&#x2019;s disease: Insight from epigenetic structure and transcriptional regulation of SNCA.</article-title> <source><italic>Prog. Neurobiol.</italic></source> <volume>154</volume> <fpage>21</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2017.04.004</pub-id> <pub-id pub-id-type="pmid">28445713</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jankovic</surname> <given-names>J.</given-names></name> <name><surname>Tan</surname> <given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Parkinson&#x2019;s disease: Etiopathogenesis and treatment.</article-title> <source><italic>J. Neurol. Neurosurg. Psychiatry</italic></source> <volume>91</volume> <fpage>795</fpage>&#x2013;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp-2019-322338</pub-id> <pub-id pub-id-type="pmid">32576618</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarome</surname> <given-names>T.</given-names></name> <name><surname>Devulapalli</surname> <given-names>R.</given-names></name></person-group> (<year>2018</year>). <article-title>The ubiquitin-proteasome system and memory: Moving beyond protein degradation.</article-title> <source><italic>Neurosci</italic></source> <volume>24</volume> <fpage>639</fpage>&#x2013;<lpage>651</lpage>. <pub-id pub-id-type="doi">10.1177/1073858418762317</pub-id> <pub-id pub-id-type="pmid">29529924</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname> <given-names>S.</given-names></name> <name><surname>Fishman-Jacob</surname> <given-names>T.</given-names></name> <name><surname>Youdim</surname> <given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Modeling sporadic Parkinson&#x2019;s disease by silencing the ubiquitin E3 ligase component, SKP1A.</article-title> <source><italic>Parkinsonism Relat. Disord.</italic></source> <volume>15</volume>(<issue>Suppl. 3</issue>), <fpage>S148</fpage>&#x2013;<lpage>S151</lpage>. <pub-id pub-id-type="doi">10.1016/S1353-8020(09)70803-X</pub-id> <pub-id pub-id-type="pmid">20082978</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname> <given-names>S.</given-names></name> <name><surname>Fishman-Jacob</surname> <given-names>T.</given-names></name> <name><surname>Youdim</surname> <given-names>M.</given-names></name></person-group> (<year>2012b</year>). <article-title>Targeting Skp1, an ubiquitin E3 ligase component found decreased in sporadic Parkinsons Disease.</article-title> <source><italic>Neurodegener. Dis.</italic></source> <volume>10</volume> <fpage>220</fpage>&#x2013;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1159/000333223</pub-id> <pub-id pub-id-type="pmid">22205206</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname> <given-names>S.</given-names></name> <name><surname>Fishman-Jacob</surname> <given-names>T.</given-names></name> <name><surname>Youdim</surname> <given-names>M.</given-names></name></person-group> (<year>2012a</year>). <article-title>Genetic reduction of the E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson&#x2019;s disease.</article-title> <source><italic>Parkinsonism Relat. Disord.</italic></source> <volume>18</volume>(<issue>Suppl. 1</issue>), <fpage>S177</fpage>&#x2013;<lpage>S179</lpage>. <pub-id pub-id-type="doi">10.1016/S1353-8020(11)70055-4</pub-id> <pub-id pub-id-type="pmid">22166427</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname> <given-names>S.</given-names></name> <name><surname>Grunblatt</surname> <given-names>E.</given-names></name> <name><surname>Riederer</surname> <given-names>P.</given-names></name> <name><surname>Amariglio</surname> <given-names>N.</given-names></name> <name><surname>Jacob-Hirsch</surname> <given-names>J.</given-names></name> <name><surname>Rechavi</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Gene expression profiling of sporadic Parkinson&#x2019;s disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits. SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.</article-title> <source><italic>Ann. N. Y. Acad. Sci.</italic></source> <volume>1053</volume> <fpage>356</fpage>&#x2013;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1344.031</pub-id> <pub-id pub-id-type="pmid">16179542</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname> <given-names>F.</given-names></name> <name><surname>Soehn</surname> <given-names>A.</given-names></name> <name><surname>Berg</surname> <given-names>D.</given-names></name> <name><surname>Melle</surname> <given-names>C.</given-names></name> <name><surname>Schiesling</surname> <given-names>C.</given-names></name> <name><surname>Lang</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein&#x2013;implications for Parkinson&#x2019;s disease.</article-title> <source><italic>FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.</italic></source> <volume>21</volume> <fpage>1759</fpage>&#x2013;<lpage>1767</lpage>. <pub-id pub-id-type="doi">10.1096/fj.06-6734com</pub-id> <pub-id pub-id-type="pmid">17327361</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehra</surname> <given-names>S.</given-names></name> <name><surname>Sahay</surname> <given-names>S.</given-names></name> <name><surname>Maji</surname> <given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>&#x03B1;-Synuclein misfolding and aggregation: Implications in Parkinson&#x2019;s disease pathogenesis.</article-title> <source><italic>Biochim. Biophys. Acta Proteins Proteomics</italic></source> <volume>1867</volume> <fpage>890</fpage>&#x2013;<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2019.03.001</pub-id> <pub-id pub-id-type="pmid">30853581</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molochnikov</surname> <given-names>L.</given-names></name> <name><surname>Rabey</surname> <given-names>J.</given-names></name> <name><surname>Dobronevsky</surname> <given-names>E.</given-names></name> <name><surname>Bonuccelli</surname> <given-names>U.</given-names></name> <name><surname>Ceravolo</surname> <given-names>R.</given-names></name> <name><surname>Frosini</surname> <given-names>D.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A molecular signature in blood identifies early Parkinson&#x2019;s disease.</article-title> <source><italic>Mol. Neurodegener.</italic></source> <volume>7</volume>:<issue>26</issue>. <pub-id pub-id-type="doi">10.1186/1750-1326-7-26</pub-id> <pub-id pub-id-type="pmid">22651796</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname> <given-names>T.</given-names></name> <name><surname>Tao</surname> <given-names>K.</given-names></name> <name><surname>Zhu</surname> <given-names>L.</given-names></name> <name><surname>Huang</surname> <given-names>L.</given-names></name> <name><surname>Hu</surname> <given-names>S.</given-names></name> <name><surname>Yang</surname> <given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Chaperone-mediated autophagy controls the turnover of E3 ubiquitin ligase MARCHF5 and regulates mitochondrial dynamics.</article-title> <source><italic>Autophagy</italic></source> <volume>17</volume> <fpage>2923</fpage>&#x2013;<lpage>2938</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2020.1848128</pub-id> <pub-id pub-id-type="pmid">33970775</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papagiannakis</surname> <given-names>N.</given-names></name> <name><surname>Xilouri</surname> <given-names>M.</given-names></name> <name><surname>Koros</surname> <given-names>C.</given-names></name> <name><surname>Stamelou</surname> <given-names>M.</given-names></name> <name><surname>Antonelou</surname> <given-names>R.</given-names></name> <name><surname>Maniati</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Lysosomal alterations in peripheral blood mononuclear cells of Parkinson&#x2019;s disease patients.</article-title> <source><italic>Mov. Disord.</italic></source> <volume>30</volume> <fpage>1830</fpage>&#x2013;<lpage>1834</lpage>. <pub-id pub-id-type="doi">10.1002/mds.26433</pub-id> <pub-id pub-id-type="pmid">26769460</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prajjwal</surname> <given-names>P.</given-names></name> <name><surname>Flores Sanga</surname> <given-names>H.</given-names></name> <name><surname>Acharya</surname> <given-names>K.</given-names></name> <name><surname>Tango</surname> <given-names>T.</given-names></name> <name><surname>John</surname> <given-names>J.</given-names></name> <name><surname>Rodriguez</surname> <given-names>R.</given-names></name></person-group> (<year>2023</year>). <article-title>Parkinson&#x2019;s disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment.</article-title> <source><italic>Ann. Med. Surg.</italic></source> <volume>85</volume> <fpage>4887</fpage>&#x2013;<lpage>4902</lpage>. <pub-id pub-id-type="doi">10.1097/MS9.0000000000001142</pub-id> <pub-id pub-id-type="pmid">37811009</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rabey</surname> <given-names>J.</given-names></name> <name><surname>Yarden</surname> <given-names>J.</given-names></name> <name><surname>Dotan</surname> <given-names>N.</given-names></name> <name><surname>Mechlovich</surname> <given-names>D.</given-names></name> <name><surname>Riederer</surname> <given-names>P.</given-names></name> <name><surname>Youdim</surname> <given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Creation of a gene expression classifier for predicting Parkinson&#x2019;s disease rate of progression.</article-title> <source><italic>J. Neural. Transm.</italic></source> <volume>127</volume> <fpage>755</fpage>&#x2013;<lpage>762</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-020-02194-y</pub-id> <pub-id pub-id-type="pmid">32385576</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname> <given-names>G.</given-names></name> <name><surname>Copetti</surname> <given-names>M.</given-names></name> <name><surname>Arcuti</surname> <given-names>S.</given-names></name> <name><surname>Martino</surname> <given-names>D.</given-names></name> <name><surname>Fontana</surname> <given-names>A.</given-names></name> <name><surname>Logroscino</surname> <given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.</article-title> <source><italic>Neurology</italic></source> <volume>86</volume> <fpage>566</fpage>&#x2013;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000002350</pub-id> <pub-id pub-id-type="pmid">26764028</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salas-Leal</surname> <given-names>A.</given-names></name> <name><surname>Salas-Pacheco</surname> <given-names>S.</given-names></name> <name><surname>Gavil&#x00E1;n-Ceniceros</surname> <given-names>J.</given-names></name> <name><surname>Castellanos-Ju&#x00E1;rez</surname> <given-names>F.</given-names></name> <name><surname>M&#x00E9;ndez-Hern&#x00E1;ndez</surname> <given-names>E.</given-names></name> <name><surname>La Llave-Le&#x00F3;n</surname> <given-names>O.</given-names></name></person-group> (<year>2021</year>). <article-title>&#x03B1;-syn and SNP rs356219 as a potential biomarker in blood for Parkinson&#x2019;s disease in Mexican Mestizos.</article-title> <source><italic>Neurosci. Lett.</italic></source> <volume>754</volume>:<issue>135901</issue>. <pub-id pub-id-type="doi">10.1016/j.neulet.2021.135901</pub-id> <pub-id pub-id-type="pmid">33865938</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname> <given-names>I.</given-names></name> <name><surname>Kaut</surname> <given-names>O.</given-names></name> <name><surname>Khazneh</surname> <given-names>H.</given-names></name> <name><surname>deBoni</surname> <given-names>L.</given-names></name> <name><surname>Ahmad</surname> <given-names>A.</given-names></name> <name><surname>Berg</surname> <given-names>D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>L-dopa increases &#x03B1;-synuclein DNA methylation in Parkinson&#x2019;s disease patients in vivo and in vitro.</article-title> <source><italic>Mov. Disord.</italic></source> <volume>30</volume> <fpage>1794</fpage>&#x2013;<lpage>1801</lpage>. <pub-id pub-id-type="doi">10.1002/mds.26319</pub-id> <pub-id pub-id-type="pmid">26173746</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soldner</surname> <given-names>F.</given-names></name> <name><surname>Stelzer</surname> <given-names>Y.</given-names></name> <name><surname>Shivalila</surname> <given-names>C.</given-names></name> <name><surname>Abraham</surname> <given-names>B.</given-names></name> <name><surname>Latourelle</surname> <given-names>J.</given-names></name> <name><surname>Barrasa</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Parkinson-associated risk variant in distal enhancer of &#x03B1;-synuclein modulates target gene expression.</article-title> <source><italic>Nature</italic></source> <volume>533</volume> <fpage>95</fpage>&#x2013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1038/nature17939</pub-id> <pub-id pub-id-type="pmid">27096366</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>J.</given-names></name> <name><surname>Kim</surname> <given-names>B.</given-names></name> <name><surname>Nguyen</surname> <given-names>D.</given-names></name> <name><surname>Samidurai</surname> <given-names>M.</given-names></name> <name><surname>Choi</surname> <given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Levodopa (L-DOPA) attenuates endoplasmic reticulum stress response and cell death signaling through DRD2 in SH-SY5Y neuronal cells under &#x03B1;-synuclein-induced toxicity.</article-title> <source><italic>Neuroscience</italic></source> <volume>358</volume> <fpage>336</fpage>&#x2013;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.06.060</pub-id> <pub-id pub-id-type="pmid">28687316</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname> <given-names>J.</given-names></name> <name><surname>Huang</surname> <given-names>P.</given-names></name> <name><surname>Qin</surname> <given-names>M.</given-names></name> <name><surname>Lu</surname> <given-names>Q.</given-names></name> <name><surname>Sang</surname> <given-names>X.</given-names></name> <name><surname>Cai</surname> <given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson&#x2019;s disease models.</article-title> <source><italic>Cell Death Dis.</italic></source> <volume>9</volume>:<issue>1020</issue>. <pub-id pub-id-type="doi">10.1038/s41419-018-1066-z</pub-id> <pub-id pub-id-type="pmid">30282965</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname> <given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>The proteasome: Overview of structure and functions.</article-title> <source><italic>Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.</italic></source> <volume>85</volume> <fpage>12</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.2183/pjab.85.12</pub-id> <pub-id pub-id-type="pmid">19145068</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taravini</surname> <given-names>I.</given-names></name> <name><surname>Larramendy</surname> <given-names>C.</given-names></name> <name><surname>Gomez</surname> <given-names>G.</given-names></name> <name><surname>Saborido</surname> <given-names>M.</given-names></name> <name><surname>Spaans</surname> <given-names>F.</given-names></name> <name><surname>Fresno</surname> <given-names>C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson&#x2019;s disease.</article-title> <source><italic>Neuropharmacology</italic></source> <volume>101</volume> <fpage>576</fpage>&#x2013;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.04.018</pub-id> <pub-id pub-id-type="pmid">25963416</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tolosa</surname> <given-names>E.</given-names></name> <name><surname>Wenning</surname> <given-names>G.</given-names></name> <name><surname>Poewe</surname> <given-names>W.</given-names></name></person-group> (<year>2006</year>). <article-title>The diagnosis of Parkinson&#x2019;s disease.</article-title> <source><italic>Lancet Neurol.</italic></source> <volume>5</volume> <fpage>75</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(05)70285-4</pub-id> <pub-id pub-id-type="pmid">16361025</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>T.</given-names></name> <name><surname>Severijnen</surname> <given-names>L.</given-names></name> <name><surname>van der Weiden</surname> <given-names>M.</given-names></name> <name><surname>Zheng</surname> <given-names>P.</given-names></name> <name><surname>Oostra</surname> <given-names>B.</given-names></name> <name><surname>Hukema</surname> <given-names>R.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>FBXO7 immunoreactivity in &#x03B1;-synuclein-containing inclusions in Parkinson disease and multiple system atrophy.</article-title> <source><italic>J. Neuropathol. Exp. Neurol.</italic></source> <volume>72</volume> <fpage>482</fpage>&#x2013;<lpage>488</lpage>. <pub-id pub-id-type="doi">10.1097/NEN.0b013e318293c586</pub-id> <pub-id pub-id-type="pmid">23656991</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>N.</given-names></name> <name><surname>Schulman</surname> <given-names>B.</given-names></name> <name><surname>Song</surname> <given-names>L.</given-names></name> <name><surname>Miller</surname> <given-names>J.</given-names></name> <name><surname>Jeffrey</surname> <given-names>P.</given-names></name> <name><surname>Wang</surname> <given-names>P.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.</article-title> <source><italic>Nature</italic></source> <volume>416</volume> <fpage>703</fpage>&#x2013;<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1038/416703a</pub-id> <pub-id pub-id-type="pmid">11961546</pub-id></citation></ref>
</ref-list>
</back>
</article>